Case Studies
Case Studies
How Rosellini’s IP strategy drives commercialization, licensing, and portfolio value across the life sciences and deep-tech sectors.
IP Monetization & Litigation
Monetizing a Medical Device Patent Portfolio for a Fortune 500 Acquirer
Following a major medical device acquisition, the acquiring company held a large spinal device patent portfolio with significant unrealized licensing value. The portfolio contained foundational claims in vertebral augmentation and kyphoplasty, but no structured monetization campaign had been executed.
Rosellini conducted comprehensive patent claim mapping across the portfolio, identified infringement targets, and developed a monetization strategy that included licensing outreach and enforcement actions. The campaign required detailed claim construction analysis, prior art evaluation for defensive positioning, and market assessment of infringing products across the orthopedic and spinal device sectors.
The monetization campaign generated significant licensing revenue from the portfolio, transforming dormant IP assets into a measurable revenue stream for the portfolio holder. The structured approach to claim mapping and market analysis became a repeatable framework for subsequent engagements.
Neuromodulation & FDA Strategy
First FDA-Approved Vagus Nerve Stimulation Therapy for Stroke Rehabilitation
A novel neurostimulation approach, paired vagus nerve stimulation (VNS) combined with rehabilitation exercises, had strong preclinical evidence for promoting neuroplasticity in stroke patients. However, the technology required a patent portfolio that could withstand competitive challenges, support FDA premarket approval (PMA), and establish a defensible commercial position in the emerging neuromodulation market.
Rosellini developed the foundational patent strategy for the company’s paired plasticity platform, building a portfolio of over a dozen U.S. patents covering timing-based neurostimulation methods (US 9,089,707; 9,345,886; 11,116,933), tinnitus treatment protocols (US 8,934,967), and wireless MEMS-based neurostimulator hardware. The IP strategy was designed to create overlapping claim coverage across device, method-of-treatment, and system claims, establishing barriers to entry across multiple potential competitive vectors.
The technology achieved FDA approval for stroke rehabilitation and PTSD treatment, becoming the first approved paired VNS therapy. The patent portfolio provided the commercial exclusivity necessary to attract clinical investment, support 10+ clinical studies, and secure regulatory approval. The work was recognized with an Edison Award for innovation.
IP Strategy & Public Offering
AI-Enhanced Surgical Imaging: From University Lab to Public Markets
An optical coherence tomography (OCT) imaging platform with potential applications in intraoperative margin detection for oncology surgery needed a comprehensive IP strategy to support its transition from academic research to a publicly traded medical device company. The technology landscape included competing imaging modalities and well-funded incumbents.
Rosellini developed the patent portfolio strategy for the company, encompassing AI-enhanced imaging algorithms, real-time surgical margin assessment methods, and hardware claims for the OCT imaging system. The IP strategy included competitive landscape analysis to identify white space for patent filings, freedom-to-operate assessments against existing imaging patents, and portfolio positioning to support investor due diligence ahead of a public offering.
The company successfully completed its public offering on the Toronto Stock Exchange. The structured IP portfolio provided investors with confidence in the company’s defensible market position and supported ongoing R&D partnerships integrating artificial intelligence with intraoperative imaging.
Pipeline Strategy & Licensing
Repositioning a Biotech Pipeline and Securing a Global Commercialization Partner
A clinical-stage biotechnology company focused on regulatory T cell (Treg) biology for neuroinflammation had a promising but unfocused pipeline. The company needed strategic IP and business guidance to refocus its therapeutic approach, raise capital through a public offering, and secure a commercialization partner for its lead ALS program.
Rosellini provided strategic IP and commercialization consulting for the company, helping to refocus the pipeline from a T-cell-centric approach to an IL-2 and combination therapy strategy with stronger IP positioning. This included evaluating the patent landscape for the repositioned pipeline, supporting the company’s IPO process (raising $15.25M), and leading negotiations for a global commercialization partnership.
The company completed a successful $15.25M public offering and secured a commercialization agreement with a major global pharmaceutical company for its ALS therapeutic program. The pipeline repositioning, grounded in IP landscape analysis, strengthened the company’s competitive position and attracted a major pharmaceutical partner.
Technology IP Enforcement
Patent Enforcement Against Major Technology Platforms
A patent portfolio with claims covering core social networking and digital platform functionalities was being infringed by several major technology companies. The portfolio holder needed a rigorous infringement analysis and litigation strategy to pursue enforcement against well-resourced defendants.
Rosellini conducted detailed claim mapping and infringement analysis against the products and services of multiple major technology platforms, including social networking, professional networking, and microblogging services. The work included prior art evaluation to assess the portfolio’s validity position, claim construction analysis, and identification of the strongest enforcement targets based on revenue exposure and claim overlap.
The enforcement campaign proceeded against multiple major technology companies. Rosellini’s claim mapping and infringement analysis provided the technical foundation for the litigation, demonstrating Rosellini’s capability to operate across both life sciences and technology IP domains.
Non-Dilutive Funding & Government IP
Securing $50M+ in Non-Dilutive Funding Through IP-Driven Grant Strategy
Deep-tech startups developing medical devices and neurotechnology needed to fund early-stage R&D without excessive equity dilution. Federal funding programs (NIH SBIR/STTR, DoD, DARPA) offered a pathway, but required strong IP positions and technically rigorous applications that demonstrated both innovation and commercial potential.
Rosellini developed IP-centered grant strategies that aligned patent portfolio positions with federal funding program requirements. This included conducting patentability assessments to demonstrate novelty, mapping existing IP landscapes to show technical differentiation, and structuring applications to highlight the commercial pathway from patented technology to clinical or defense application. Rosellini also provided expert testimony to Congress on the NIH SBIR program, contributing to policy discussions on innovation funding.
Clients secured over $50M in cumulative non-dilutive funding across NIH, DoD, and DARPA programs. The IP-driven approach to grant strategy preserved equity for founders while funding critical development milestones including FDA submissions, prototype development, and clinical studies.